BACKGROUND AND OBJECTIVES: Soluble TNF-like weak inducer of apoptosis (sTWEAK) and long pentraxin-3 (PTX3) concentrations have been associated with endothelial function in patients with chronic kidney disease (CKD). This study tested the hypothesis that the improvement in endothelial function after initiation of angiotensin II receptor blocker (valsartan), calcium channel blocker (amlodipine) therapy, or a combination of both is directly linked to the normalization of sTWEAK and PTX3. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: One-hundred-eight diabetic CKD stage I patients with hypertension (56% men, 46.7+/-5.3 years) were allocated to a 12-week intervention with amlodipine (10 mg/d), valsartan (160 mg/d), or their combination. Plasma levels of sTWEAK, PTX3, and flow-mediated dilation (FMD) were studied during the interventions. RESULTS: All treatment strategies effectively increased FMD and reduced proteinuria, confirming a more prone reduction with the combined therapy. These improvements were followed by significant PTX3 reductions. Valsartan alone and in combination with amlodipine achieved significant incremental raises in sTWEAK plasma levels. More importantly, the changes observed in sTWEAK (beta=0.25, P=0.006) or PTX3 (beta=-0.24, P=0.007) plasma levels were independently associated with the improvement in ultrasonographically measured FMD. CONCLUSIONS: This study shows that treatment with antihypertensive drugs improves FMD and normalizes proteinuria, PTX3, and sTWEAK in diabetic CKD stage I patients with hypertension. The improvement in FMD was independently associated with PTX3 and sTWEAK normalization. Two surrogate biomarkers of endothelial function are therefore identified with potential as therapeutic targets. The study was registered in clinicaltrials.gov as NCT00921570.
RCT Entities:
BACKGROUND AND OBJECTIVES: Soluble TNF-like weak inducer of apoptosis (sTWEAK) and long pentraxin-3 (PTX3) concentrations have been associated with endothelial function in patients with chronic kidney disease (CKD). This study tested the hypothesis that the improvement in endothelial function after initiation of angiotensin II receptor blocker (valsartan), calcium channel blocker (amlodipine) therapy, or a combination of both is directly linked to the normalization of sTWEAK and PTX3. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: One-hundred-eight diabetic CKD stage Ipatients with hypertension (56% men, 46.7+/-5.3 years) were allocated to a 12-week intervention with amlodipine (10 mg/d), valsartan (160 mg/d), or their combination. Plasma levels of sTWEAK, PTX3, and flow-mediated dilation (FMD) were studied during the interventions. RESULTS: All treatment strategies effectively increased FMD and reduced proteinuria, confirming a more prone reduction with the combined therapy. These improvements were followed by significant PTX3 reductions. Valsartan alone and in combination with amlodipine achieved significant incremental raises in sTWEAK plasma levels. More importantly, the changes observed in sTWEAK (beta=0.25, P=0.006) or PTX3 (beta=-0.24, P=0.007) plasma levels were independently associated with the improvement in ultrasonographically measured FMD. CONCLUSIONS: This study shows that treatment with antihypertensive drugs improves FMD and normalizes proteinuria, PTX3, and sTWEAK in diabetic CKD stage Ipatients with hypertension. The improvement in FMD was independently associated with PTX3 and sTWEAK normalization. Two surrogate biomarkers of endothelial function are therefore identified with potential as therapeutic targets. The study was registered in clinicaltrials.gov as NCT00921570.
Authors: B Bottazzi; V Vouret-Craviari; A Bastone; L De Gioia; C Matteucci; G Peri; F Spreafico; M Pausa; C D'Ettorre; E Gianazza; A Tagliabue; M Salmona; F Tedesco; M Introna; A Mantovani Journal: J Biol Chem Date: 1997-12-26 Impact factor: 5.157
Authors: Begoña Muñoz-García; Jose Luis Martín-Ventura; Elena Martínez; Santiago Sánchez; Gonzalo Hernández; Luis Ortega; Alberto Ortiz; Jesús Egido; Luis Miguel Blanco-Colio Journal: Stroke Date: 2006-06-29 Impact factor: 7.914
Authors: Y Chicheportiche; P R Bourdon; H Xu; Y M Hsu; H Scott; C Hession; I Garcia; J L Browning Journal: J Biol Chem Date: 1997-12-19 Impact factor: 5.157
Authors: David H Ho; Hong Vu; Sharron A N Brown; Patrick J Donohue; Heather N Hanscom; Jeffrey A Winkles Journal: Cancer Res Date: 2004-12-15 Impact factor: 12.701
Authors: Jonas Axelsson; Holger Jon Møller; Anna Witasp; Abdul Rashid Qureshi; Juan Jesus Carrero; Olof Heimbürger; Peter Bárány; Anders Alvestrand; Bengt Lindholm; Søren K Moestrup; Peter Stenvinkel Journal: Am J Kidney Dis Date: 2006-12 Impact factor: 8.860
Authors: V Buda; M Andor; C Cristescu; M Voicu; F Cochera; P Tuduce; L Petrescu; M C Tomescu Journal: Ir J Med Sci Date: 2017-02-21 Impact factor: 1.568
Authors: Mahmut Ilker Yilmaz; Alper Sonmez; Alberto Ortiz; Mutlu Saglam; Selim Kilic; Tayfun Eyileten; Kayser Caglar; Yusuf Oguz; Abdulgaffar Vural; Mustafa Çakar; Jesus Egido; Battal Altun; Mujdat Yenicesu; Luis Miguel Blanco-Colio; Juan Jesús Carrero Journal: Clin J Am Soc Nephrol Date: 2011-02-17 Impact factor: 8.237
Authors: Elizabeth R Flynn; David C Marbury; R Taylor Sawyer; Jonathan Lee; Christine Teutsch; Katalin Kauser; Christine Maric-Bilkan Journal: Nephron Extra Date: 2012-07-06